Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Pharma large Merck is shopping for US biotech agency Terns Pharmaceuticals for $6.7 billion, the corporate mentioned Wednesday.
This is the third multibillion-dollar acquisition for Merck over the previous yr as the corporate seems to be to bulk up its portfolio forward of its best-selling cancer drug Keytruda dropping patent safety in 2028.
Merck will purchase Terns for $53 per share in money for an fairness worth of about $6.7 billion. That marks a 6% premium to Tuesday’s closing value, in accordance to CNBC’s calculations. The deal is anticipated to shut within the second quarter.
Terns is creating a drugs for a sort of leukemia that analysts see as a multibillion-dollar drug that would finally rival Novartis‘Scemblix.
Terns’ inventory has skyrocketed in latest months with investor pleasure constructing over the experimental drug, which confirmed promising leads to an early trial late final yr.
Terns shares rose 5.3% whereas Merck’s inventory was largely flat in premarket buying and selling on Wednesday. Shares of Terns have been up as a lot as 15% in earlier buying and selling after media reviews mentioned the businesses have been nearing a deal.
Terns inventory has skyrocketed over the previous yr.
This is breaking information. Please refresh for updates.
